Improving Mitochondrial Function to Protect against Myocardial Ischemia/Reperfusion
Improving Mitochondrial Function to Protect against Myocardial Ischemia/Reperfusion
批准号:
9908162
负责人:
QINGLIN YANG
金额:
$36.75万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-05 至 2022-01-31
关键词:
ATP HydrolysisATP Synthesis PathwayAdenovirusesAffectAttenuatedBiochemicalCardiacCardiac MyocytesCardiac Surgery proceduresCardiomyopathiesCardiovascular systemChickensClinicalCongestive Heart FailureCouplingDefectDependovirusDiseaseDown SyndromeEnergy MetabolismEnhancersEnzymesEscherichia coliGene TargetingGenerationsGenesHeartImpairmentIn VitroIschemiaKnock-outKnockout MiceLeadMediatingMetabolicMitochondriaMitochondrial ProteinsMitochondrial Proton-Translocating ATPasesMolecularMorphologyMultienzyme ComplexesMusMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumNamesOrganOutcomeOxidation-ReductionOxidative PhosphorylationPPAR alphaPatientsPerformancePeroxisome Proliferator-Activated ReceptorsPilot ProjectsPlayProductionProteinsProtonsRegulationReperfusion InjuryReperfusion TherapyReservationsRespirationRoleSatellite VirusesSerotypingSignal TransductionSkeletal MuscleStructureTamoxifenTestingTherapeuticTissuesTransgenic OrganismsTroponin TViral VectorWorkbasegain of functiongene therapygenetic manipulationgenomic locusheart metabolismhuman diseaseimprovedin vivoinnovationinsightischemic cardiomyopathymitochondrial membranemitochondrial metabolismmouse modelnew therapeutic targetnoveloverexpressionpre-clinicalpreventpromotersuccesstherapeutic gene
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Myocardial ischemia/reperfusion (IR) injury is the main clinical challenge of adverse
cardiovascular outcomes after myocardial ischemia, cardiac surgery or circulatory arrest.
It is well established that myocardial ATP depletion is a key feature of myocardial
ischemia and heart failure1. Improving myocardial energy metabolism has been a well-
known target to protect the heart from IR injury, but with little success. "
ATP synthase is a key enzyme complex generating ATP in mitochondria, thus playing a
central role in mitochondrial function. Functional defects of ATP synthase can cause and
aggravate human diseases, such as cardiomyopathy and congestive heart failure.
However, our understanding of the regulation of energy metabolism and mitochondrial
function in the energy demanding heart remains poor. We have recently identified a
PPAR-target gene encoding a novel mitochondrial protein ES1 with unknown function.
Preliminary studies revealed that ES1 is a mitochondrial protein interacting with the
subunits α and β of ATP synthase F1 sector. We were excited to find that ES1 works as
an enhancer of ATP production by increasing ATP synthesis and inhibiting ATP
hydrolysis. However, it remains unknown if ES1 similarly regulates ATP production in the
heart subjected to myocardial IR. Interestingly, our preliminary studies revealed that ES1
protein levels were decreased in hearts with myocardial IR injury of patients and mice.
Based on the pilot studies on conditional transgenic and gene targeting mouse lines, we
hypothesize that ES1 is a novel therapeutic target of protecting the heart from
myocardial IR via its role in facilitating cardiac energy production/reservation. To
test this central hypothesis, we will first define the role of ES1 as an endogenous
regulator of ATP synthase and as a determinant of mitochondrial structure/function in the
heart. We will then determine if transgenic and adenoviral-associated virus-mediated
ES1 overexpression in the heart protects the heart against myocardial IR injury by its
role in regulating energy metabolism. These studies will provide novel insights into how
to manipulate energy metabolism to protect the heart from myocardial IR injury.
Furthermore, these new fundamental scientific findings will have broader implications in
diseases related to other organs and tissues.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bbadis.2021.166237
发表时间:
2021-11-01
期刊:
Biochimica et biophysica acta. Molecular basis of disease
影响因子:
--
作者:
[Liu Z, Gao X, Zhou Z, Kang SW, Yang Y, Liu H, Zhang C, Wen Z, Rao X, Wang D, White D 3rd, Yang Q, Long Q]
通讯作者:
Long Q
DOI:
10.3390/cells12050695
发表时间:
2023-02-22
期刊:
Cells
影响因子:
6
作者:
[]
通讯作者:
DOI:
10.1038/s41374-021-00670-x
发表时间:
2022-01
期刊:
LABORATORY INVESTIGATION
影响因子:
5
作者:
[Zhang, Kailiang, Bao, Rong, Huang, Fengyuan, Yang, Kevin, Ding, Yishu, Lauterboeck, Lothar, Yoshida, Masasuke, Long, Qinqiang, Yang, Qinglin]
通讯作者:
Yang, Qinglin
Energetic State and Metabolic Remodeling in Cardiac Hypertrophy and Failure
-
批准号:10522598
-
项目类别:
-
资助金额:$49.12万
-
财政年份:2022
-
负责人:QINGLIN YANG
-
依托单位:
Energetic State and Metabolic Remodeling in Cardiac Hypertrophy and Failure
-
批准号:10704664
-
项目类别:
-
资助金额:$49.0万
-
财政年份:2022
-
负责人:QINGLIN YANG
-
依托单位:
Restore energy capacity in the aging heart
-
批准号:9297564
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2017
-
负责人:QINGLIN YANG
-
依托单位:
Improving mitochondrial function to protect against myocardial ischemia/reperfusion
-
批准号:9218501
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2017
-
负责人:QINGLIN YANG
-
依托单位:
Regulation of myocardial lipid and energy homeostasis
-
批准号:7683461
-
项目类别:
-
资助金额:$6.67万
-
财政年份:2008
-
负责人:QINGLIN YANG
-
依托单位:
Regulation of myocardial lipid and energy homeostasis
-
批准号:7763254
-
项目类别:
-
资助金额:$44.08万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Regulation of myocardial lipid and energy homeostasis
-
批准号:7624429
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Regulation of myocardial lipid and energy homeostasis
-
批准号:7198412
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Effects of Salacia oblonga root extract on cardiac hypertrophy
-
批准号:7497576
-
项目类别:
-
资助金额:$21.32万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Regulation of myocardial lipid and energy homeostasis
-
批准号:7568937
-
项目类别:
-
资助金额:$44.08万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Effects of Salacia oblonga root extract on cardiac hypertrophy
-
批准号:7318889
-
项目类别:
-
资助金额:$4.32万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
Effects of Salacia oblonga root extract on cardiac hypertrophy
-
批准号:7637625
-
项目类别:
-
资助金额:$13.18万
-
财政年份:2007
-
负责人:QINGLIN YANG
-
依托单位:
PPARgamma signaling pathway in cardiac hypertrophy and failure
-
批准号:7268773
-
项目类别:
-
资助金额:$34.47万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPARgamma signaling pathway in cardiac hypertrophy and failure
-
批准号:7452410
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPARgamma signaling pathway in cardiac hypertrophy and failure
-
批准号:7652423
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPAR-delta in Cardiac Hypertrophy and Heart Failure
-
批准号:7162845
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPARgamma signaling pathway in cardiac hypertrophy and failure
-
批准号:7880923
-
项目类别:
-
资助金额:$35.2万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPARgamma signaling pathway cardiac hypertrophy/failure
-
批准号:7134088
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2006
-
负责人:QINGLIN YANG
-
依托单位:
PPAR-delta in Cardiac Hypertrophy and Heart Failure
-
批准号:7906786
-
项目类别:
-
资助金额:$20.75万
-
财政年份:--
-
负责人:QINGLIN YANG
-
依托单位:
PPAR-delta in Cardiac Hypertrophy and Heart Failure
-
批准号:7690384
-
项目类别:
-
资助金额:$18.46万
-
财政年份:--
-
负责人:QINGLIN YANG
-
依托单位: